AbbVie campaign focuses on women with HIV
NORTH CHICAGO, Ill. – Drug maker AbbVie is launching an international awareness campaign focused on women living with HIV, the drug maker said Tuesday.
World AIDS Day is on Dec. 1, and in advance of the event, the company announced the launch of the campaign, dubbed See Us: Women Take a Stand on HIV. The campaign is being launched in collaboration with an expert steering committee that includes representation from women living with and affected by HIV, the medical community, the International Association of Providers in AIDS Care and the HIV information group NAM/aidsmap.
According to UNAIDS, women are the fastest-growing group within the population of living with HIV around the world and face many challenges that compound the effects of the infection itself, its associated stigmas and the status of women. Problems include lack of access to care, discrimination and violence, as well as unique maternal and emotional health issues, according to the Department of Health and Human Services.
Hospira announces investor conference
LAKE FOREST, Ill. — Generic drug maker Hospira will have its investor conference next week, the company said Tuesday.
The drug maker, based in the Chicago area, will have the investor day at its headquarters on Dec. 5. Hospira specializes in manufacturing injectable generic drugs, including biosimilars for the European market.
The event will include slide presentations, and the company will stream it via audio webcast at its investors website, hospirainvestor.com.
QRxPharma refiles application for oxycodone, morphine combination pill Moxduo
BEDMINSTER, N.J. — QRxPharma has resubmitted its regulatory approval application for an opioid painkiller for which it has sought Food and Drug Administration approval since 2011, the company said Tuesday.
The Australian drug maker announced the resubmission of its application for Moxduo, a pill that combines oxycodone and morphine.The FDA is expected to schedule an advisory committee meeting to review the application for May 2014.
"We are confident that our refiled [new drug application] will confirm the validity of the data defining the product’s respiratory safety advantages, and we are hopeful that the FDA will view them favorably in their consideration of the benefits of immediate-release Moxduo as a therapeutic option for the millions of patients who suffer from acute pain," QRxPharma CEO and managing director John Holaday said.